- Events
-
Webinar: Use of genetic data in health care
Date: 27th May
Venue: Virtual
Price: Free
Time: 14:00 - 16:00 CET
The zoom link will be distributed to the participants closer to the event.
Program
Please note that ammendments may occur.
Introduction and national updates
Speakers: Santa Slokenberga (Uppsala University), Katharina Ó Cathaoir (University of Copenhagen), Kaisa-Maria Kimmel (University of Lapland) and Oda Bakken (Oslo University Hospital).
More information
Short national updates related to genetic data in health care from a legal perspective will be given from Sweden, Denmark, Finland and Norway.
Genetic data in personalized medicine: possibilities and potential challenges
Speaker: Eirik Joakim Tranvåg, senior adviser at the Norwegian Biotechnology Advisory Board
More information
The use of genetic data is a key element in the personalized medicine paradigm, where better health can be achieved by tailoring prevention, diagnostics and treatment to each patient’s individual biological characteristics. This talk will give a short overview of how genetic data is currently used in personalized medicine in Norway and how its use can be imagined in the future. In the end some ethical concerns related to personalized medicine will be discussed.
Secondary use of genetic data – business perspective to regulation
Speaker: Sandra Liede, lawyer, Regulatory Affairs at Healthtech Finland
More information
Sandra Liede from Healthtech Finland shares insights on the use of genetic date within business contexts, and experiences from the health technology sector regarding secondary use regulation in Finland.
Equal access to treatment involving the use of genetic data
Speakers: Mirjami Tran Minh, Communications and Public Affairs Specialist, Cancer IO, Helsinki University and Kaisa-Maria Kimmel, researcher, Faculty of Law, University of Lapland
More information
Mirjami Tran Minh from the University of Helsinki coordinated Cancer IO research project and Kaisa-Maria Kimmel from the University of Lapland discuss equal access to health care, and structural challenges specific to treatments involving the use of genetic data.